The casualties in the Clostridium difficile vaccine race are starting to pile up. Having been vaulted to the front of the queue by Sanofi’s failure, Pfizer has now missed the primary endpoint in its ...
Pfizer hosted a discussion with sell-side analysts to provide an update on one of the vaccine pipeline items – a second-generation Clostridioides difficile (C. diff) vaccine effort in Phase 2.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback